TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04296058

Intervention type: OTHER
Intervention: microvessel density
Description: the vessel numbers in high power field with Anti-CD31 staining in tumor specimen
Study: NCT01350492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: 16 weeks of resistance exercise training for the treatment of chronic muscle pain compared to wait-list control
Study: NCT00993083

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1
Description: Intramuscular injection at 1.5 x 10\^8 pfu/ml at day 0
Study: NCT05827510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-585F
Description: BTL-585F device with BTL-585-4 applicator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-585F
Description: BTL-585F device with BTL-585-4 applicator
Study: NCT01842672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Dose Escalation of Clofarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Study: NCT03149146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Making (CDM) Workshop
Description: Participants will be provided the Clinical Decision Making workbook which will be used as a guideline to practice decision making. A workshop was chosen rather than other methods of presenting the guideline so that participants could receive feedback and guidance from the instructors and from the other participants. Active learning educational environment will be encouraged and the workshop require group and individual participation and also assist the participants in reflection on their decisions.
Study: NCT04763694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifocal soft contact lenses
Description: Myopic subjects wore multifocal soft contact lenses for 12 months
Study: NCT06258603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral care bundle
Description: In the first stage, oral health was evaluated and data about the patient was collected.~In the second stage, an oral care bundle containing an oral care combination was applied to the experimental group. According to this bundle application, patients were received tooth brushing (with chlorhexidine solution) and ice water application twice a day and moisturizing attempts 4 times a day.~In the 3rd stage, saliva pH, dry mouth (amount of salivation) and ventilator associated pneumonia development status of the experimental group patients were evaluated.~Measurements were made by the researcher using the Bedside Oral Exam scale, pH (power of hydrogen) strip and Schirmer Tear Test Strip.~Data regarding whether patients were diagnosed with ventilator associated pneumonia were obtained from the Infection Control Committee.

Intervention type: OTHER
Group type: OTHER
Intervention: clinical oral care
Description: In the first stage, oral health was evaluated and data about the patient was collected.~In the second stage, routine oral care protocol used in intensive care unit was applied to patients by the patients' primary nurse. According to this application, patients were received oral care using tongue depressor with wrapped in gauze and chlorhexidine solution 4 times a day.~In the 3rd stage, saliva pH (power of hydrogen), dry mouth (amount of salivation) and ventilator associated pneumonia development status of the experimental group patients were evaluated.~Measurements were made by the researcher using the Bedside Oral Exam scale, pH (power of hydrogen) strip and Schirmer Tear Test Strip.~Data regarding whether patients were diagnosed with ventilator associated pneumonia were obtained from the Infection Control Committee.
Study: NCT03886987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue Non Sterile Powder Free Nitrile Examination Gloves
Description: Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
Study: NCT00902031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docusate Sodium, Sennoside
Description: Docusate sodium: given in capsule form (100 mg/capsule), at a dosage of 200 mg, taken twice daily for 10 days.~Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sennoside + Placebo
Description: Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.~Placebo: will be taken in capsule form, similar in size, shape, and color to docusate, taken twice daily for 10 days
Study: NCT01307839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% lidocaine patch
Description: Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours
Study: NCT03275636

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cells
Description: Hematopoietic stem cell transplantation with PBSC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral blood stem cells
Description: Hematopoietic stem cell transplantation with PBSC
Study: NCT04401865

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Description: Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Description: Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
Study: NCT03255655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Therapeutic Ultrasound Treatment - ITU

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intense Therapeutic Ultrasound Treatment - ITU
Study: NCT01673243

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire data will be collected one time from parents who enroll on the study during their child's regular clinical visit. We will use a cross-sectional design to estimate the proportion of smoking parents of children with or surviving cancer, or sickle cell disease (SCD) who are willing to participate in tobacco trials, hypothetically offered in the context of their child's medical care. We will also examine the contribution of sociodemographic, environmental, and psychosocial variables, as well as, smoking behaviors as they relate to a parent's willingness to participate in a tobacco-related study.

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire data will be collected one time from parents who enroll on the study during their child's regular clinical visit. We will use a cross-sectional design to estimate the proportion of smoking parents of children with or surviving cancer, or sickle cell disease (SCD) who are willing to participate in tobacco trials, hypothetically offered in the context of their child's medical care. We will also examine the contribution of sociodemographic, environmental, and psychosocial variables, as well as, smoking behaviors as they relate to a parent's willingness to participate in a tobacco-related study.

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire data will be collected one time from parents who enroll on the study during their child's regular clinical visit. We will use a cross-sectional design to estimate the proportion of smoking parents of children with or surviving cancer, or sickle cell disease (SCD) who are willing to participate in tobacco trials, hypothetically offered in the context of their child's medical care. We will also examine the contribution of sociodemographic, environmental, and psychosocial variables, as well as, smoking behaviors as they relate to a parent's willingness to participate in a tobacco-related study.
Study: NCT00208806

Intervention type: OTHER
Intervention: congestive heart failure patients
Description: observational echo data on congestive heart failure patients
Study: NCT03809988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy
Description: Endocrine therapy alone (letrozole or fulvestrant)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Endocrine therapy alone (letrozole or fulvestrant)
Study: NCT01697566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken by mouth twice daily for 4, 30 day cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo taken by mouth twice daily for 4, 30 day cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Biopsy
Description: Endometrial biopsies obtained at baseline and after 4 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Biopsy
Description: Endometrial biopsies obtained at baseline and after 4 months.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endometrial Biopsy
Description: Endometrial biopsies obtained at baseline and after 4 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Biopsy
Description: Endometrial biopsies obtained at baseline and after 4 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.
Study: NCT03149146

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Decision Making (CDM) Workbook
Description: Participants are encouraged to read and do exercises which was written in the workbook for a week and they also are asked to recall their recent patient case or use their patient as the example case and answer the questions from the Clinical Decision Making workbook.
Study: NCT03749824

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: Omega-3 supplement is a highly concentrated fish oil brain booster supplement that helps compensate for the neurocognitive and brain dysfunction which acts as a predisposition to antisocial and violent behaviour. Individuals with antisocial personality disorder have been found to show an 11% reduction in gray matter in the prefrontal cortex (Raine et al. 2001), and structural prefrontal impairments are hypothesised to result in disinhibition of limbic subcortical structures that give rise to aggressive behaviour. Omega-3 (specifically DHA) is known to play a key role in neuronal structure and function.
Study: NCT00610649

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally administered matching placebo capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally administered matching placebo capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally administered matching placebo capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally administered matching placebo capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally administered matching placebo capsules.
Study: NCT04252586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: GWP42003-P presented as an oral solution containing cannabidiol in the excipients sesame oil with anhydrous ethanol, sweetener (sucralose), and strawberry flavoring
Study: NCT02469727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook group
Description: Participants will receive and post messages and receive badges on the Facebook group
Study: NCT04064086

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Pre-ESRD Patient Education (CPE)
Description: Structured education session/s

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Provision of the freely available resources for Kidney Disease Education
Description: freely available resources
Study: NCT03749824

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months.
Study: NCT00456625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: Intramuscular injection, 1 dose
Study: NCT01419600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8683
Description: Single Dose Inhaled IMP via Turbuhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match
Description: Single dose Inhaled Placebo via Turbuhaler
Study: NCT02370992

Intervention type: RADIATION
Intervention: I125 brachytherapy
Description: I125 brachytherapy is a standard treatment and will be delivered using routine techniques involving a preimplant volume study followed by implantation of the I125 sources. This is undertaken as an inpatient or day case under general or spinal anaesthetic according to local practice
Study: NCT04538131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sensor-driven position-adaptive SCS
Description: Medtronic sensor-driven position-adaptive SCS is capable to monitor the position change and change the parameters accordingly, so as to reduce the position change related side effects.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional SCS
Description: Conventional SCS can not change the parameter when the body position changes.
Study: NCT03676010

Intervention type: OTHER
Intervention: Sarcoma and GIST
Description: No Intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.

Intervention type: OTHER
Intervention: Breast cancer
Description: No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.

Intervention type: OTHER
Intervention: Pancreatic cancer
Description: No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
Study: NCT00041470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: 20 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: 4 mg/kg IV loading dose day 1 of first week followed by 2 mg/kg IV maintenance dose on each subsequent week. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 mcg/kg daily including the day of IV chemotherapy. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
Study: NCT01453491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRT2104
Description: SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 25mg or 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule. All subjects will be provided with one dosing bottle per day that contains two 25 mg or 250 mg SRT2104 capsules for oral ingestion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRT2104
Description: SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 25mg or 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule. All subjects will be provided with one dosing bottle per day that contains two 25 mg or 250 mg SRT2104 capsules for oral ingestion.
Study: NCT03930589

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic conditioning
Description: BP cuff inflation for 5 min and deflation for 5 mins with 4 cycles

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study: NCT04791293

Intervention type: OTHER
Intervention: MELD-Na score
Description: MELD-Na scores will be compared between the groups

Intervention type: OTHER
Intervention: MELD-Na score
Description: MELD-Na scores will be compared between the groups
Study: NCT02573571

Intervention type: OTHER
Intervention: Development of biomarkers
Description: Blood sampling
Study: NCT00754689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimonabant
Description: Tablet, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Tablet, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Tablet, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Tablet, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Tablet, oral administration
Study: NCT02951897

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: lobectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lobectomy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: lobectomy
Study: NCT01449123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol challenge test & reversibility test
Description: Patients perform an asthma control test (ACT) to establish if they are well controlled or symptomatic. All patients will perform then perform the mannitol challenge test. Aridol™ is an indirect osmotic bronchial challenge test which can be used to identify bronchial hyperresponsiveness
Study: NCT00754689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablet, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablet, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Tablet, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Tablet, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Tablet, oral administration
Study: NCT03782064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a monoclonal antibody. Antibodies are part of your immune system; they are a type of protein that protects your body against foreign invaders, called antigens, by grabbing hold of antigens to stop them from invading your system. Nivolumab has been shown to react against cancer cells, including MM cells.
Study: NCT03676010

Intervention type: OTHER
Intervention: Renal cell carcinoma
Description: No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.

Intervention type: OTHER
Intervention: Colon cancer
Description: No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy (adjuvant setting).
Study: NCT03782064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC/myeloma fusions/GM-CSF
Description: The DC/MM vaccine is an investigational agent that tries to help the immune system recognize and fight against cancer cells, utilizing unique markers.
Study: NCT01697566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of questionnaires about diet and exercise at baseline, during treatment and at end of study. Questionnaires take about 30-40 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of questionnaires about diet and exercise at baseline, during treatment and at end of study. Questionnaires take about 30-40 minutes to complete.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Completion of questionnaires about diet and exercise at baseline, during treatment and at end of study. Questionnaires take about 30-40 minutes to complete.
Study: NCT03182283

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Person-centered psychosis care
Description: Person-centered care educational intervention for staff with following implementation of person-centered care in the clinic
Study: NCT02099084

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Teduglutide
Description: Participants will receive Teduglutide 0.05 mg/kg/d administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Participants will receive Teduglutide 0.05 mg/kg/d administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching study drug, administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching study drug, administered subcutaneously.